Many interesting papers presented during the CARDIOCON 2017 held at Hyderabad


Many interesting papers presented during 

the CARDIOCON 2017 held at Hyderabad

HYDERABAD: Many interesting papers were presented during the CARDIOCON 2017 organized by Pakistan Cardiac Society held at Hyderabad from November 24-26, 2017. Prof. Feroz Memon was the convener of CARDIOCON 2017 which was very well attended by cardiologist and physicians from all over the country.

 Prof. M. Hafizullah along with Prof. Abdul Hafeez Chaudhary and Dr. M. Abubakar Sheikh chaired the preventive cardiology session. Dr. Bilal S. Mohyudin from Punjab Institute of cardiology Lahore was the first speaker and topic of his presentation was “Own Your Heart” What more we can do? Dr. M. Naeem Malik from PIMS Islamabad discussed Noval Risk Factors for Coronary Artery Disease. Dr. Saulat Siddique from Punjab Medical Centre, Lahore talked about Can a single blood test predict heart disease in general population and Prof. M. Hafeezullah discussed how to write more effectively and publish.

Session on Learning Heart Rhythms was chaired by Zahid Jamal along with Dr. Asad Saleem while Dr. Azam Shafqat acted as Moderator. Dr. Azam Shafqat from Riyadh talked about leadless cardiac pacing. Dr. Amir Hameed from AKU, Karachi presented the update in IST & POTS. Dr. Asad Saleem from Shifa Hospital Islamabad discussed SVT EKGs, Dr. Fariha Sadiq Ali from Tabba Heart Institute, Karachi discussed management of SVTs. Dr. Zahid Jamal from NICVD Karachi talked about wide complex tachycardia’s EKGs. Dr. Ghazala Irfan also from NICVD discussed the management of VT in structurally normal heart, Dr. Faisal Qadir discussed Afib EKGs and Dr. Muhammad Shabbir also from NICVD Karachi talked about anticoagulation for atrial fibrillation.

Prof. Ejaz Ahmed Vohra, Prof. M. Ishaq and some others delegates photographed alongwith Prof. Bika
Ram Devrajani Vice Chancellor of Liaquat University of Medical & Health Sciences Hyderabad
at the Cardiocon
2017 held at Hyderabad recently.

Prof. Azhar Masood Faruqui along with Dr. Saulat Siddique and Dr. Bilal S. Mohyauddin chaired session on Ischemic Heart Disease. Dr. Muhammad Abubakr Sheikh from AKU, Karachi was the first speaker in this session and topic of his presentation was Is CAD an inflammatory Disease? Dr. Suhail Abrar Khan from Tabba Heart Institute Karachi discussed the role of Echocardiography in ACS. Burden of Atherosclerosis Risk in Pakistani Population, a hidden health challenge was highlighted by Prof. Tariq Ashraf from NICVD, Karachi. Prof. Abdul Hafeez Chaudhary from Independent University Hospital Faisalabad talked about RASS blockade and cardiovascular risk reduction. Dr. Fawad Farooq from NICVD Karachi discussed the ACS management in ER while Dr. Bela Khan also from NICVD, Karachi talked about risk factors and coronary angiographic profile in young patients with AMI.

Intervention in Cardiology session was chaired by Maj. Gen. (R) M.H. Nuri along with Dr. Bashir Hanif while Dr. Fasih A Hashi acted as Moderator. Dr. Javed Iqbal from Cardiac Centre Dorset County, UK highlighted the FFR & iFR practical implication. Gen. Dr. Suhail Aziz from AFIC, Rawalpindi presented Live in Box (Didactic Case). Maj. Gen. (R) M. H. Nuri from Tahir Heart Institute Rabwah discussed left main stem interventions- Life saving procedure. Dr. Jawaid Akbar Sial from NICVD Karachi shared experience of providing primary percutaneous intervention PCI services at rural cardiac center. Dr. Bashir Haneef from Tabba Heart Institute Karachi gave details about Clinical Patient Registry.

Prof. Shahid Amin, Dr. Syed Imran Ahmed and Maj. Gen. Imran Afzal were the panel of expert in session on Heart Failure. Dr. Abubakr Ali Samad acted as Moderator. Dr. Tariq Soomro from Prince Sultan Cardiac Centre Qassim, Saudi Arabia presented the Imaging in Heart Failure, Maj. Gen. Dr. Imran Fazal from Military Hospital Rawalpindi discussed current Medical Treatments of Heart Failure while Dr. Shahbaz Ahmed Kureshi from Kulsum Int. Hospital Islamabad highlighted the Drug Therapy & Atrial Fibrillation in Heart Failure.

 Prof. Borja Ibanez from Midrid, Spain highlighted the new 2017 STEMI Guidelines. Routine revascularization of non-IRA lesions, he pointed out should be considered in STEMI patients with multivessel disease before hospital discharge. Non-IRA PCI during the index procedure should be considered in patients with cardiogenic shock. In high ischemic risk patients who have tolerated DAPT without bleeding complication, treatment with DAPT in the form of ticagrelor 60mg twice a day on top of aspirin for longer than 12 months may be considered for up to three years.

Prof. Nadeem Qamar along with Prof. Zia Yaqoob chaired the session on Arguments in Cardiac Intervention. Dr. Mahesh Kumar from NICVD, Karachi talked about Contrast –Induced AKI: the sin of primary percutaneous coronary intervention? Dr. Bashir Ahmed also from NICVD, Karachi discussed cardiogenic shock complicating acute MI stem. Dr. Bashir Hanif and Dr. Saulat Fatmi discussed Multivessel PCI v/s CABG respectively.

Pakistan Cardiac Society organized its annual conference at Hyderabad last month. Group photograph
taken during the conference shows some participants and organizers of the conference with Prof. Bika
Ram Devrajani Vice Chancellor of Liaquat University of Medical & Health Sciences Hyderabad.

Clinical Cardiology session was chaired by Prof. Bekha Ram along with Prof. Muhammad Ishaq and Prof. Saeed Ahmed Sanghi. Prof. Ejaz Ahmed Vohra talking about the role of Statins in Ischemic Heart Diseases said that statins are the proven most effective in reducing cardiovascular morbidity and mortality. The minimal nature of adverse side effects can be prevented by more knowledge regarding interactions and dosages. Physicians are advised to continue prescribing statins where indicated as per recommendations. Primary prevention without Diabetes Mellitus and Hypertension should be done with life style intervention only. Residual Cardiovascular risk in patients optimally on statins continues to be a problem. Further reduction of LDL-C beyond the target of ≤70 mg/dL in high risk patients has shown benefits, targeting other lipid components, such as triglycerides or LPa, may also be beneficial. Some recent studies eg, (CANTOS) have highlighted the values of interventions to treat vascular inflammation. CEPT Inhibitor trial has also showed promising result, he concluded.

Prof. Muhammad Ishaq talking about safety and efficacy of Noval Oral Anticoagulants (NOACs) said that they are at least as effective as Warfarin and are replacing Warfarin for NVAF and its indications are expected to expand. NOACs can be given in fixed dose and need no mentoring, and less liable to cause ICH vs Warfarin. Its safety for VAF mechanical valve is not yet established. Most bleeding can be managed without specific antidotes and specific antidotes under development will enhance physician’s confidence, he added. Dr. Junaid Zafar from Fatima Jinnah Medical University, Lahore discussed venous thromboembolism, How long we need to go? While role of proBNP in Heart Failure was discussed by Dr. Kaleemullah Sheikh from KIHD, Karachi.

Pakistan Cardiac Society and American Council of Cardiology joint webinar was moderated by Prof. Azhar Masood A Faruqui. Dr. Vinod Thourani from MedStar Heart Vascular Institute, Washington USA talked about TAVR, its indications outcome and future prospective. Dr. Vinod informed that Since 2007 more than two thousand TAVR gets enrolled. From 2012 to 2017, one hundred one thousand two hundred sixty four procedure has been done and overall mortality has gown down. TAVR valves are approved in the USA and two more are anticipated in the next twenty four months. TAVR, he stated is the standard of care for those considered high and extreme risk for SAVR. TAVR is now the majority of cases for those considered intermediate risk for SAVR. Two randomized trials are near completion for low risk TAVR vs SAVR trails in the United State. Two new TAVR valves are to start trials next year for AS and AR (Jenavalve). Further refinement in device technology and minimizing complications remain paramount, he concluded.

Dr. Christie Ballantyne from Baylor College of Medicine USA talked about PCSK9 inhibitors in view of recent trial, its cost effectiveness v/s benefits. Talking about ODYSSEY outcome he informed that eighteen thousand six hundred men and women ages ≥40 years with ACS ≤52 weeks before randomization. Randomized to receive biweekly alirocumab (75mg or 150mg, titrated to achieve LDL-C≥25 mg/dL and <50 mg/dL) or placebo. Primary efficacy measures time to first occurrence of CHD death, nonfatal MI, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina. Duration is sixty four months, (four month run in, 60 months randomized treatment ≥ 2 years follow-up). Estimated completion time is December 2017. Lower is better for CV outcome and longer duration of therapy is better. No safety signal for very low LDL-C of <20 over 1 to 2 years. Reduction in first event does not reflect the full benefit on the total event reduction. The highest risk patients (recent MI, multivessel CAD, PAD, and highest TIMI risk score) have the greatest benefit. Absolute risk of the patient and amount of LDL-C reduction can be used to predict the absolute benefit of therapy and the cost effectiveness of therapy, he added.

Dr. Zakiuddin Ahmed talked about Patients safety and quality healthcare in session of “Ethics in clinical Practice”. Cancer and medical error are the leading cause of death in America. Only 15% Medical errors are reported, imagine if reported 100% it will be the leading cause of death. It is system problem, which could be controlled and need team work of healthcare providers.

Mr. Qasim Ali Shah, Professional Motivational Speaker talked about value of wellbeing & goal setting in Doctors Life. Most of the doctors, he pointed out do not know about any other thing except their profession. They are successful doctor but not successful husbands. They are just like ATM machines. We have time for everything in life except our own self. People are technically good, but have behavior problem, that’s why are not successful in practice. We have got much success in our life while we are still unhappy and trying to get it. There are many people in the World who always worry about future and all the time thinking about it. You have to love people around you, forgive their mistakes, learn knowledge about rather than your profession, help others in terms of professional and as well as other scenarios, do not backbite, perform your responsibility with honesty and dedication, do not practice ego even if you are guilty and accept your mistake. This will really help you to get peace and happiness in your life. You need people to celebrate your success and happiness, so you should make some friends as well and spend time with family and friends and should spare more time for them.

Session on Valvular Heart Diseases, Congenital Heart Disease, Women and Cardiovascular diseases, Cardiac Surgeons and Cardiologist Together, Cardiology in special groups were also part of the CARDIOCON 2017.

© Professional Medical Publications. All rights reserved.